Axepta: Advanced Neuropathic Pain Relief with Pregabalin
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.44 | $34.40 (0%) | 🛒 Add to cart |
| 20 | $1.94 | $68.80 $38.70 (44%) | 🛒 Add to cart |
| 30 | $1.43 | $103.20 $43.00 (58%) | 🛒 Add to cart |
| 60 | $0.79 | $206.40 $47.30 (77%) | 🛒 Add to cart |
| 90 | $0.57 | $309.60 $51.60 (83%) | 🛒 Add to cart |
| 120 | $0.50 | $412.80 $60.20 (85%) | 🛒 Add to cart |
| 180 | $0.48 | $619.20 $86.00 (86%) | 🛒 Add to cart |
| 270 | $0.46 | $928.80 $124.70 (87%) | 🛒 Add to cart |
| 360 | $0.43
Best per pill | $1238.40 $154.80 (88%) | 🛒 Add to cart |
| Product dosage: 18mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.87 | $38.70 (0%) | 🛒 Add to cart |
| 20 | $2.15 | $77.40 $43.00 (44%) | 🛒 Add to cart |
| 30 | $1.58 | $116.10 $47.30 (59%) | 🛒 Add to cart |
| 60 | $1.00 | $232.20 $60.20 (74%) | 🛒 Add to cart |
| 90 | $0.96 | $348.30 $86.00 (75%) | 🛒 Add to cart |
| 120 | $0.93 | $464.40 $111.80 (76%) | 🛒 Add to cart |
| 180 | $0.86 | $696.60 $154.80 (78%) | 🛒 Add to cart |
| 270 | $0.80 | $1044.90 $215.00 (79%) | 🛒 Add to cart |
| 360 | $0.75
Best per pill | $1393.20 $270.90 (81%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.30 | $43.00 (0%) | 🛒 Add to cart |
| 20 | $2.36 | $86.00 $47.30 (45%) | 🛒 Add to cart |
| 30 | $1.72 | $129.00 $51.60 (60%) | 🛒 Add to cart |
| 60 | $1.29 | $258.00 $77.40 (70%) | 🛒 Add to cart |
| 90 | $1.24 | $387.00 $111.80 (71%) | 🛒 Add to cart |
| 120 | $1.15 | $516.00 $137.60 (73%) | 🛒 Add to cart |
| 180 | $0.96 | $774.00 $172.00 (78%) | 🛒 Add to cart |
| 270 | $0.86 | $1161.00 $232.20 (80%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $1548.00 $258.00 (83%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.16 | $51.60 (0%) | 🛒 Add to cart |
| 20 | $3.01 | $103.20 $60.20 (42%) | 🛒 Add to cart |
| 30 | $3.15 | $154.80 $94.60 (39%) | 🛒 Add to cart |
| 60 | $2.87 | $309.60 $172.00 (44%) | 🛒 Add to cart |
| 90 | $2.48 | $464.40 $223.60 (52%) | 🛒 Add to cart |
| 120 | $2.15 | $619.20 $258.00 (58%) | 🛒 Add to cart |
| 180 | $1.86 | $928.80 $335.40 (64%) | 🛒 Add to cart |
| 270 | $1.43 | $1393.20 $387.00 (72%) | 🛒 Add to cart |
| 360 | $1.19
Best per pill | $1857.60 $430.00 (77%) | 🛒 Add to cart |
Axepta is a prescription medication containing pregabalin, a potent anticonvulsant and analgesic agent specifically formulated for the management of neuropathic pain. It operates by binding to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, effectively modulating the release of several excitatory neurotransmitters. This targeted mechanism reduces neuronal hyperexcitability, which is a hallmark of neuropathic pain conditions. Clinicians favor Axepta for its proven efficacy, predictable pharmacokinetic profile, and well-established safety data across numerous randomized controlled trials. It represents a first-line therapeutic option for patients suffering from peripheral and central neuropathic pain syndromes.
Features
- Active ingredient: Pregabalin
- Available strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg film-coated tablets
- Mechanism of action: Binds potently to the alpha2-delta subunit of voltage-gated calcium channels
- Pharmacokinetics: Linear kinetics, rapid absorption (Tmax ~1 hour), high bioavailability (>90%)
- Excretion: Primarily renal (unchanged)
- Half-life: Approximately 6.3 hours
- Specialized formulation for consistent drug release and tolerability
Benefits
- Provides significant reduction in neuropathic pain scores as measured by visual analog scales (VAS) and neuropathic pain scales
- Improves sleep quality and reduces pain-related sleep interference through central nervous system modulation
- Enhances overall quality of life and functional capacity in patients with chronic neuropathic conditions
- Demonstrates rapid onset of analgesic effect, often within the first week of treatment
- Offers flexible dosing options to accommodate individual patient needs and renal function
- Supported by extensive clinical evidence from phase III trials and real-world studies
Common use
Axepta (pregabalin) is primarily indicated for the management of neuropathic pain. This includes painful diabetic neuropathy, characterized by burning, shooting, or stabbing pain in the extremities resulting from diabetic nerve damage. It is also effectively employed in postherpetic neuralgia, the persistent neuropathic pain that follows an acute episode of herpes zoster infection. Additionally, Axepta is used as adjunctive therapy for adults with partial onset seizures, and for the management of fibromyalgia. Off-label uses may include other neuropathic pain conditions such as spinal cord injury-related pain, phantom limb pain, and chemotherapy-induced peripheral neuropathy, though these should be considered under specialist supervision.
Dosage and direction
The initial dosage of Axepta for neuropathic pain is 150 mg per day, administered orally in two or three divided doses (e.g., 75 mg twice daily or 50 mg three times daily). Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3-7 days. If needed, and if well tolerated, the dose can be further increased to a maximum of 600 mg per day after an additional 7-day interval. For patients with renal impairment, dosage adjustment is necessary: creatinine clearance 30-60 mL/min: maximum 300 mg/day; 15-30 mL/min: maximum 150 mg/day; <15 mL/min: maximum 75 mg/day. Tablets should be swallowed whole with water, with or without food. Abrupt discontinuation should be avoided; taper gradually over a minimum of one week.
Precautions
Axepta may cause dizziness and somnolence, which could impair physical and mental abilities required for driving or operating machinery. Patients should be cautioned about performing hazardous activities until they are reasonably certain Axepta does not adversely affect them. There is a potential for weight gain; regular monitoring of body weight is advised. Peripheral edema may occur, particularly in patients taking concomitant thiazolidinedione antidiabetic drugs. Patients with a history of drug abuse should be closely monitored. Ophthalmological effects including blurred vision have been reported; periodic eye examinations are recommended during prolonged therapy. Caution is advised in patients with congestive heart failure.
Contraindications
Axepta is contraindicated in patients with known hypersensitivity to pregabalin or any excipients in the formulation. It should not be used in patients with severe hepatic impairment due to limited clinical data in this population. The combination with thiazolidinedione antidiabetic agents is contraindicated in patients with pre-existing risk factors for heart failure. Use during pregnancy is contraindicated unless clearly necessary and after careful risk-benefit assessment, due to potential fetal harm demonstrated in animal studies. Breastfeeding is not recommended during treatment with Axepta.
Possible side effect
The most commonly reported adverse reactions (≥10%) include dizziness, somnolence, dry mouth, peripheral edema, blurred vision, weight gain, and disturbances in attention. Less frequent side effects (1-10%) may include constipation, euphoric mood, balance disorder, increased appetite, fatigue, speech disorder, tremor, lethargy, memory impairment, erectile dysfunction, and nausea. Serious but rare adverse effects (<1%) include angioedema, hypersensitivity reactions, rhabdomyolysis, decreased platelet count, and creatine kinase elevation. Suicidal ideation and behavior have been reported in a small percentage of patients; close monitoring for mood changes is essential.
Drug interaction
Axepta has minimal drug-drug interactions as it is not metabolized by cytochrome P450 enzymes and does not inhibit or induce these enzymes. However, concomitant use with central nervous system depressants (including opioids, benzodiazepines, barbiturates, and alcohol) may potentiate cognitive and motor impairment. Thiazolidinedione antidiabetic agents may increase the risk of peripheral edema and weight gain when combined with Axepta. Co-administration with angiotensin-converting enzyme inhibitors may increase the risk of angioedema. Pregabalin may enhance the effects of ethanol and lorazepam. No clinically significant interactions have been observed with oral contraceptives, glyburide, insulin, or digoxin.
Missed dose
If a dose of Axepta is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Maintaining consistent blood levels is important for optimal efficacy, so adherence to the prescribed schedule is recommended. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy, as dose adjustment may be necessary.
Overdose
Symptoms of Axepta overdose may include pronounced drowsiness, sedation, confusion, restlessness, agitation, depression, seizures, and cardiac conduction abnormalities. In cases of significant overdose, respiratory depression and coma may occur. There is no specific antidote for pregabalin overdose. Management should include general supportive measures and symptomatic treatment. Gastric lavage may be considered if performed soon after ingestion. Hemodialysis may be effective in removing pregabalin from the bloodstream (approximately 50% reduction in 4 hours) and should be considered in cases of severe overdose, particularly in patients with renal impairment. Maintain adequate airway and ventilation; monitor cardiac function and vital signs.
Storage
Store Axepta tablets at room temperature (15-30°C or 59-86°F) in their original packaging to protect from moisture and light. Keep the container tightly closed. Do not store in bathrooms or other areas with high humidity. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly dispose of any unused or expired medication through medication take-back programs or according to local regulations. Do not flush medications down the toilet or pour them into a drain unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Axepta is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Dosage and treatment duration should be individualized based on the patient’s medical condition, renal function, and response to therapy. Patients should not initiate, adjust, or discontinue Axepta without consulting their physician. The manufacturer and distributor are not liable for any damages resulting from the use or misuse of this information. Always refer to the official prescribing information for complete details.
Reviews
Clinical studies demonstrate that Axepta (pregabalin) provides significant pain relief in approximately 40-50% of patients with diabetic neuropathy and postherpetic neuralgia, with number needed to treat (NNT) values ranging from 4.2 to 5.9 for 50% pain reduction. Systematic reviews and meta-analyses confirm its efficacy superiority over placebo with standardized mean differences of -0.68 for neuropathic pain. Real-world evidence supports maintained efficacy over 12 months of treatment in responsive patients. Patient-reported outcomes indicate meaningful improvements in sleep quality, mood, and overall quality of life. The most common reasons for discontinuation in clinical trials were dizziness (6.8%) and somnolence (4.4%). Overall, Axepta remains a well-established, evidence-based option for neuropathic pain management with a favorable risk-benefit profile when appropriately prescribed and monitored.